{"disease":{"id":"the-focus-of-the-study-is-to-reduce-the-risk-of-stroke-and-life-threatening-bleeding-events-in-patients-with-non-valvular-atrial-fibrillation","name":"the focus of the study is to reduce the risk of stroke and life threatening bleeding events in patients with non valvular atrial fibrillation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05324371","title":"WATCHMAN FLX™ CT Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}